Press Releases

Date Title
11/29/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/14/19 Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies
11/7/19 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
11/5/19 Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference
10/31/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/24/19 Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019
10/4/19 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
9/30/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/25/19 Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
9/5/19 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
Displaying 61 - 70 of 660